A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to ...

Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...

Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...

Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on ...

CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management ...

(“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of ...

China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to ...

Leading institutions will evaluate StarGuide GX i across quantitative imaging, dynamic imaging and emerging theranostic ...

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission ...

RxMP Therapeutics, Inc. ("RxMP"), a late pre-clinical stage therapeutics company developing novel therapies for the rapid ...